Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Pfizer
(NY:
PFE
)
25.40
+0.14 (+0.55%)
Official Closing Price
Updated: 7:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
46,526,519
Open
25.33
Bid (Size)
25.41 (2)
Ask (Size)
25.45 (9)
Prev. Close
25.26
Today's Range
25.20 - 25.54
52wk Range
25.20 - 40.37
Shares Outstanding
5,606,688,356
Dividend Yield
6.46%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
3 Dividend Stocks to Buy and Hold for the Next Decade
Today 7:15 EDT
You'll get dividends and more with these great stocks.
Via
The Motley Fool
7 Dividend Stocks to Buy Now for Steady Returns in Any Market
Today 6:00 EDT
Passive investors pay attention! Invest in the best of the best with these seven dividend stocks for steady returns.
Via
InvestorPlace
Performance
YTD
-14.56%
-14.56%
1 Month
-8.57%
-8.57%
3 Month
-7.54%
-7.54%
6 Month
-15.64%
-15.64%
1 Year
-34.43%
-34.43%
More News
Read More
COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle
April 26, 2024
Via
Benzinga
Topics
Intellectual Property
Lawsuit
Exposures
COVID-19
Financial
Intellectual Property
FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia
April 26, 2024
Via
Benzinga
Exposures
Product Safety
Pfizer's Options: A Look at What the Big Money is Thinking
April 26, 2024
Via
Benzinga
Creative Biolabs: The Way ADCs Are Made Has Changed
April 23, 2024
Via
Get News
US Stock: Pfizer
April 23, 2024
Via
Talk Markets
Pfizer Options Trading: A Deep Dive into Market Sentiment
April 22, 2024
Via
Benzinga
Want $2,000 in Annual Dividends? Invest $30,000 in These 3 Stocks
April 26, 2024
Via
The Motley Fool
Pfizer Now Rivals The World's Most Expensive Medicine After FDA Approves Gene Therapy
April 26, 2024
Via
Investor's Business Daily
Exposures
Product Safety
U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
April 26, 2024
From
Pfizer Inc.
Via
Business Wire
What's Going On With Pfizer Stock On Thursday?
April 25, 2024
Via
Benzinga
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
3 Bargain Stocks Near 52-week Lows
April 25, 2024
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
April 25, 2024
Via
Investor's Business Daily
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
April 25, 2024
Via
Benzinga
Pfizer Declares Second-Quarter 2024 Dividend
April 24, 2024
From
Pfizer Inc.
Via
Business Wire
The Top 7 Dividend Stocks to Buy in 2024 to Build Lasting Wealth
April 24, 2024
Via
InvestorPlace
3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains
April 24, 2024
Via
InvestorPlace
3 Defensive Stocks To Protect Your Portfolio In 2024
April 23, 2024
Via
Talk Markets
Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown
April 23, 2024
Via
Benzinga
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
3 Underappreciated Pharmaceutical Stocks to Buy Before They Surge
April 23, 2024
Via
InvestorPlace
Better Buy: Pfizer vs. Viking Therapeutics
April 23, 2024
Via
The Motley Fool
1 No-Brainer Vanguard Fund to Buy Right Now
April 23, 2024
Via
The Motley Fool
3 Blue-Chip Stocks That Will Beat Index Returns Over the Next 3 Years
April 22, 2024
Via
InvestorPlace
European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options
April 22, 2024
From
Pfizer Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.